Takeda Pharmaceutical Co. (TAK)
(Real Time Quote from BATS)
$13.26 USD
-0.12 (-0.90%)
Updated Apr 24, 2024 02:02 PM ET
3-Hold of 5 3
A Value D Growth C Momentum C VGM
Price, Consensus and EPS Surprise
TAK 13.26 -0.12(-0.90%)
Will TAK be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TAK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TAK
OPKO Health (OPK) And Entera Bio Announce Data for GLP-2
Takeda Pharmaceutical Co. (TAK) Upgraded to Buy: What Does It Mean for the Stock?
TAK: What are Zacks experts saying now?
Zacks Private Portfolio Services
TAK or STVN: Which Is the Better Value Stock Right Now?
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
Protagonist (PTGX) Up 14% on Licensing Deal With Takeda
Other News for TAK
Takeda Pharmaceutical: A Long-Term Cash Cow
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
Neurocrine succeeds in mid-stage trial for Takeda-partnered depression drug
Takeda, Astellas and Sumitomo to create new drug discovery company
Takeda, Astellas Pharma and Sumitomo Mitsui to establish joint venture company